By indication / Neuroendocrine neoplasms
Neuroendocrine neoplasms
20 imaging agents and 35 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [68Ga]Ga-DOTA-TOC paired with [177Lu]Lu-DOTA-TOC | Ga-68 | Approved | 40 |
| [18F]FDOPA | F-18 | Approved | 26 |
| [68Ga]Ga-DOTATATE paired with [177Lu]Lu-DOTATATE | Ga-68 | Approved | 26 |
| [18F]SiTATE | F-18 | — | 6 |
| [68Ga]Ga-DOTANOC paired with [47Sc]Sc-DOTANOC | Ga-68 | — | 6 |
| [18F]FETrp | F-18 | Research | 5 |
| [18F]AmBF3-TATE | F-18 | Preclinical | 3 |
| [18F]AlF-NOTA-octreotide | F-18 | — | 2 |
| [68Ga]Ga-DOTA-CP04 | Ga-68 | — | 2 |
| [64Cu]Cu-sartate paired with [67Cu]Cu-SARTATE | Cu-64 | Clinical research | 1 |
| [18F]FB(ePEG12)12-exendin-4 | F-18 | Clinical research | 1 |
| [123I]MIBG paired with [131I]MIBG | I-123 | — | 1 |
| [68Ga]TATE-46 | Ga-68 | Preclinical | 1 |
| [203Pb]eSOMA-01 | Pb-203 | Reported once | 1 |
| [203Pb]eSOMA-02 | Pb-203 | Reported once | 1 |
| [203Pb]eSOMA-03 | Pb-203 | Reported once | 1 |
| [68Ga]C803-GIP | Ga-68 | Reported once | 1 |
| [64Cu]Cu-DOTATATE paired with [177Lu]Lu-DOTATATE | Cu-64 | Approved | |
| [18F]FET-bAG-TOCA paired with [177Lu]Lu-DOTATATE | F-18 | Research | |
| [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide | Ga-68 | Clinical research |
Therapy
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [111In]In-APH070 | In-111 | Preclinical | 1 |
| [212Pb]Pb-VMT-alpha-NET | Pb-212 | Clinical research |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch